;
Skip to main content
Home > SciBX > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Figure 1: SMYD3 in cancer

    Targets & Mechanisms: Putting SMYD3 on the MAP Figure 1. SMYD3 in cancer. Mazur et al. have identified the role of SET and MYND domain containing 3 (SMYD3) in K-Ras (KRAS)-driven lung and pancreatic cancers. In …

    Published on 6/12/2014
  • Table 1: Selected MAPK pathway compounds in cancer

    Targets & Mechanisms: Putting SMYD3 on the MAP Table 1. Selected MAPK pathway compounds in cancer. Source: BCIQ: BioCentury Online Intelligence Company Compound Indication Target Status Amgen Inc. (NASDAQ:AMGN…

    Published on 6/12/2014
  • Box 1: Revisiting the pancreas

    Targets & Mechanisms: Stromal uncertainties in pancreatic cancer Box 1. Revisiting the pancreas. The insights into the nature of these aggressive, poorly differentiated pancreatic tumors suggest a niche for two …

    Published on 6/12/2014
  • Putting SMYD3 on the MAP

    Stanford and GlaxoSmithKline report that SMYD3 acts in the cytoplasm to regulate the MAPK pathway and not in the nucleus as previously thought. The discovery implies that inhibiting the enzyme can counter activating …

    Published on 6/12/2014
  • Stromal uncertainties in pancreatic cancer

    Despite the clear rationale for using hedgehog inhibitors in pancreatic cancer-they deplete the stroma to improve chemotherapy delivery-clinical results have been disappointing. New data suggest the large amounts of …

    Published on 6/12/2014
  • De-stressing glaucoma

    Glucocorticoids are standard care for a host of allergic and inflammatory eye conditions, but they can elevate intraocular pressure and result in secondary open-angle glaucoma. A chemical chaperone called sodium …

    Published on 6/5/2014
  • S100A9-clot not, bleed not

    U.S. researchers have shown that blocking S100 calcium binding protein A9 could prevent thrombosis without increasing the risk of bleeding. The findings may hand a new indication to at least two companies-InflammatoRx …

    Published on 5/29/2014
  • The DR is out

    Five years after a Genentech team proposed that DR6 was a member of a seemingly targetable pathway in Alzheimer's disease, the company and Rockefeller University have concluded that the proapoptotic pathway probably …

    Published on 5/15/2014
  • TLR4 on the surface of scleroderma

    BioLineRx's deal with the University of Colorado could give the biotech a disease-modifying therapy for cutaneous fibrosis in patients with diffuse systemic scleroderma. It remains unclear whether the university's TLR4 …

    Published on 5/8/2014
  • Figure 1: Bolstering cancer immunotherapy with IL-15

    Targets & Mechanisms: Leveling cancer with IL-15 Figure 1. Bolstering cancer immunotherapy with IL-15. (I) IL-15 is an immunostimulatory cytokine that typically is found pre-bound to the IL-15 receptor a-chain (IL-…

    Published on 4/24/2014
  • Leveling cancer with IL-15

    Findings that link high IL-15 levels in tumors with increased local T cell proliferation and favorable patient outcomes position the cytokine as a robust prognostic and complement ongoing efforts to develop IL-15 as a …

    Published on 4/24/2014
  • Mired in miR-25

    New evidence that miR-25 inhibition can help treat heart failure contradicts earlier results. Although the current study shows that blocking miR-25 restores SERCA2A -- and thus improves cardiac contractility -- …

    Published on 4/24/2014
  • Reversing (heart) failure in Friedreich's ataxia

    Heart failure accounts for over half the deaths in patients with Friedreich's ataxia, but there are no therapies for the neurodegenerative disease. Now, a team of French researchers has shown that i.v. frataxin gene …

    Published on 4/24/2014
  • Unfolding triple-negative breast cancer

    A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases…

    Published on 4/17/2014
  • Catastrophic vacuolization

    Karolinska Institute scientists have attacked glioblastoma multiforme by inducing an unconventional cell death pathway involving catastrophic vacuolization. The team identified a small molecule that prolonged survival …

    Published on 4/10/2014
  • Positioning properdin

    Researchers at the University of Leicester have shown that a recombinant properdin produced in collaboration with The Medicines Co. has markedly higher antibacterial activity than the native protein. The researchers are…

    Published on 4/10/2014
  • Narrowing down graft stenosis

    One serious complication after coronary artery bypass graft surgery is hyperplastic growth of the transplant. Now, a U.S. team has reported that this hyperplasia is rooted in the endothelial cells lining the …

    Published on 4/3/2014
  • Insights into ependymoma

    Two independent studies have revealed targets for previously intractable ependymoma tumors: a fusion protein and epigenetic modifiers, respectively. The therapeutic potential of the targets remains to be established.

    Published on 3/27/2014
  • Zinc-ing about diabetes

    ZNT8 burst onto the scene in 2007 as a promising diabetes target, and follow-up studies suggested that stimulating the zinc transporter protein could have therapeutic benefit. A new study suggests that the preferred …

    Published on 3/13/2014
  • Table 1: Cardiovascular expressions

    Targets & Mechanisms: Heart cells: no longer undivided Table 1. Cardiovascular expressions. At least 10 companies have gene therapies in preclinical through Phase III development to treat a range of cardiovascular …

    Published on 3/6/2014
  • Depending on SWI/SNF

    Loss-of-function mutations in chromatin-modifying proteins remain largely intractable. Separate teams, including a group from Novartis, have identified synthetic lethal interactions that could be exploited to help treat…

    Published on 3/6/2014
  • Heart cells: no longer undivided

    The inability of heart cells to divide rapidly enough to repair damage is a major impediment to regenerating heart tissue after myocardial infarction. A U.S. team has used cyclin A2 gene therapy to induce cardiomyocyte …

    Published on 3/6/2014
  • The XII factor

    Researchers have found that inhibiting either factor XII or factor XI can provide thromboprotection without increasing the risk of bleeding. Both targets could eliminate the main drawback of existing anticoagulants.

    Published on 2/27/2014
  • Table 1: Targeting the intrinsic pathway of coagulation and the kallikrein-kinin system

    The XII factor Table 1. Targeting the intrinsic pathway of coagulation and the kallikrein-kinin system. The intrinsic pathway and the kallikrein-kinin system are both activated by factor XIIa. The table below is a …

    Published on 2/27/2014
  • Figure 1: Factor XIIa pathways

    Targets & Mechanisms: The XII factor Figure 1. Factor XIIa pathways. The intrinsic pathway of coagulation and the kallikrein-kinin system are both activated downstream of factor XII (FXII). (I) In the intrinsic …

    Published on 2/27/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993